# Efficacy and Safety of BGB-290 in the Treatment of Metastatic HER2-Negative Breast Cancer Patients With BRCA Mutation in China

> **NCT03575065** · PHASE2 · COMPLETED · sponsor: **BeiGene** · enrollment: 88 (actual)

## Conditions studied

- HER2-negative Breast Cancer

## Interventions

- **DRUG:** BGB-290

## Key facts

- **NCT ID:** NCT03575065
- **Lead sponsor:** BeiGene
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-06-22
- **Primary completion:** 2020-10-09
- **Final completion:** 2021-04-14
- **Target enrollment:** 88 (ACTUAL)
- **Last updated:** 2024-10-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03575065

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03575065, "Efficacy and Safety of BGB-290 in the Treatment of Metastatic HER2-Negative Breast Cancer Patients With BRCA Mutation in China". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT03575065. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*